Cool Results From ZLTQ, TNDM On Watch, NEOS Resubmits NDA, Ascent Of ASND

Shares of Ascendis Pharma A/S (ASND) touched a new high on Thursday, following the company’s positive top-line results from a six-month phase II study of once-weekly TransCon Growth Hormone in 53 treatment-na‹ve, pre-pubertal children with growth hormone deficiency, or GHD.